On September 10, DUALITYBIO-B fell 5.38% in regular trading, trading at HK$173.4 per share, with turnover of approximately HK$80.69 million.

The decline was driven by a combination of disappointing interim results and broad-based weakness across the biotech sector. The company's previously disclosed H1 results showed revenue of RMB 219 million, a sharp drop from RMB 1.229 billion in the year-ago period. The adjusted net loss widened to RMB 627 million, while operating cash flow swung from a net inflow of RMB 590 million to a net outflow of RMB 424 million. Management attributed the revenue decline partly to a one-time RMB 291 million revenue deduction related to exercising the DB-1311/BNT324 US market cost-and-profit sharing option, alongside lower recognizable upfront and milestone payments.

Meanwhile, the biotech sector faced systematic selling pressure, with peers Everest Medicines down 7.37%, 3SBIO down 2.91%, Innovent Biologics down 2.34%, Akeso down 0.89%, and BeOne Medicines down 0.48%, compounding downward momentum on the stock.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)